Ajinomoto's Patent Invalidation Claims Fully Dismissed by U.S. PTAB
Aptis Maintains Validity of U.S. Patent, Securing Foundation for ADC Platform Commercialization

Aptis, a next-generation antibody-drug conjugate (ADC) drug and platform development company, announced on the 14th that it had won an inter partes review (IPR) initiated by Japan’s Ajinomoto at the Patent Trial and Appeal Board (PTAB) in the United States concerning patent invalidation.

Aptis company logo image. Aptis

Aptis company logo image. Aptis

View original image

This review was initiated by Ajinomoto, which challenged the validity of the US patent for Aptis’s ADC platform technology 'AbClick'. Through a final written decision, the PTAB dismissed all of Ajinomoto’s claims for invalidation and upheld Aptis’s core patent.


Ajinomoto argued for patent invalidation based on Section 112 of US patent law (written description, enablement, indefiniteness), as well as Section 102 (anticipation) and Section 103 (obviousness). The PTAB did not accept any of these claims and also dismissed arguments related to procedures and evidence. As a result of this decision, Aptis is able to maintain the validity of the key patent protecting its AbClick platform in the United States.


AbClick is a site-specific ADC platform technology that selectively conjugates drugs to a specific lysine residue (Lys248) in the antibody's Fc region. The company explains that this enables the production of ADCs with a uniform drug-to-antibody ratio (DAR), ensuring consistent product quality. Aptis is developing its own ADC pipeline based on AbClick, while also pursuing partnerships and technology transfers with domestic and overseas pharmaceutical and biotech companies.



Hyungseok Choi, CEO of Aptis, said, "This decision confirms the validity of the core patent protecting the AbClick platform in the United States," adding, "Building on the technological and patent competitiveness of AbClick, we will expand global partnerships and technology commercialization, while continuing to develop new ADC drugs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing